The Danish pharmaceutical giant Novo Nordisk, which is behind the drug Ozempic, among other things, is introducing a global hiring freeze, reports several Danish media outlets.
The freeze concerns positions that are not considered necessary for the company's continued operations, something that is confirmed by the press department of the newspaper Berlingske.
The company's new CEO Mike Doustdar announced in July that savings packages are to be expected at the pressured company.
